Loading…

Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance

The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2009-12, Vol.52 (23), p.7689-7705
Main Authors: Ghosh, Arun K, Kulkarni, Sarang, Anderson, David D, Hong, Lin, Baldridge, Abigail, Wang, Yuan-Fang, Chumanevich, Alexander A, Kovalevsky, Andrey Y, Tojo, Yasushi, Amano, Masayuki, Koh, Yasuhiro, Tang, Jordan, Weber, Irene T, Mitsuya, Hiroaki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3
cites cdi_FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3
container_end_page 7705
container_issue 23
container_start_page 7689
container_title Journal of medicinal chemistry
container_volume 52
creator Ghosh, Arun K
Kulkarni, Sarang
Anderson, David D
Hong, Lin
Baldridge, Abigail
Wang, Yuan-Fang
Chumanevich, Alexander A
Kovalevsky, Andrey Y
Tojo, Yasushi
Amano, Masayuki
Koh, Yasuhiro
Tang, Jordan
Weber, Irene T
Mitsuya, Hiroaki
description The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the protein backbone similar to darunavir (1) or inhibitor 2. The ring size, the effect of methyl substitution, and unsaturation within the macrocyclic ring structure were assessed. In general, cyclic inhibitors were significantly more potent than their acyclic homologues, saturated rings were less active than their unsaturated analogues and a preference for 10- and 13-membered macrocylic rings was revealed. The addition of methyl substituents resulted in a reduction of potency. Both inhibitors 14b and 14c exhibited marked enzyme inhibitory and antiviral activity, and they exerted potent activity against multidrug-resistant HIV-1 variants. Protein−ligand X-ray structures of inhibitors 2 and 14c provided critical molecular insights into the ligand-binding site interactions.
doi_str_mv 10.1021/jm900695w
format article
fullrecord <record><control><sourceid>acs_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_1006098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>b225873186</sourcerecordid><originalsourceid>FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3</originalsourceid><addsrcrecordid>eNptkUuOEzEQhi0EYsLAggsgC4kFUhr8Sj-WkBmYSOEhAohdq9pdnTjqtke2e1DfgDXn4TScBEeJZjasqlT6VFX__xPylLNXnAn-ej9UjOXV4uc9MuMLwTJVMnWfzBgTIhO5kGfkUQh7xpjkQj4kZ7wqVF7lckb-XGAwWzunm8nGXerDnH72LqKxf3_9Xpst2Jb-yDxMdBP9qOPocU4Pw7fG9W5rNPT08gb6EaJxlrqOAt2gNxgO_Ud3gz39ANo7PeneaHo1DmDpahhG61rsjDZo9US_Gz-GjB9vQ0C6sjvTmOh8oNHRpRsaiPTCj1v65fBlBKvxMXnQQR_wyamek2_vLr8ur7L1p_er5Zt1BqoQMVO6VFWHqXSiKDhbNEUjZaFEi7lqsBBlyQuJwLkssJHAm06xfCF0qxSHtpXn5PlxrwvR1EGbiHqnnbWoY82T9awqE_TyCCWtIXjs6mtvBvBTIupDTPVtTIl9dmSvx2bA9o485ZKAFycAQnK480muCbecEIKVbMHuONCh3rvR2-TDfw7-A1HcqYo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Ghosh, Arun K ; Kulkarni, Sarang ; Anderson, David D ; Hong, Lin ; Baldridge, Abigail ; Wang, Yuan-Fang ; Chumanevich, Alexander A ; Kovalevsky, Andrey Y ; Tojo, Yasushi ; Amano, Masayuki ; Koh, Yasuhiro ; Tang, Jordan ; Weber, Irene T ; Mitsuya, Hiroaki</creator><creatorcontrib>Ghosh, Arun K ; Kulkarni, Sarang ; Anderson, David D ; Hong, Lin ; Baldridge, Abigail ; Wang, Yuan-Fang ; Chumanevich, Alexander A ; Kovalevsky, Andrey Y ; Tojo, Yasushi ; Amano, Masayuki ; Koh, Yasuhiro ; Tang, Jordan ; Weber, Irene T ; Mitsuya, Hiroaki ; Argonne National Lab. (ANL), Argonne, IL (United States)</creatorcontrib><description>The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the protein backbone similar to darunavir (1) or inhibitor 2. The ring size, the effect of methyl substitution, and unsaturation within the macrocyclic ring structure were assessed. In general, cyclic inhibitors were significantly more potent than their acyclic homologues, saturated rings were less active than their unsaturated analogues and a preference for 10- and 13-membered macrocylic rings was revealed. The addition of methyl substituents resulted in a reduction of potency. Both inhibitors 14b and 14c exhibited marked enzyme inhibitory and antiviral activity, and they exerted potent activity against multidrug-resistant HIV-1 variants. Protein−ligand X-ray structures of inhibitors 2 and 14c provided critical molecular insights into the ligand-binding site interactions.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm900695w</identifier><identifier>PMID: 19746963</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Columbus, OH: American Chemical Society</publisher><subject>08 HYDROGEN ; AIDS VIRUS ; Anti-HIV Agents - chemical synthesis ; Anti-HIV Agents - chemistry ; Anti-HIV Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; BONDING ; Cell Line ; Crystallography, X-Ray ; DESIGN ; Drug Design ; Drug Resistance, Viral - drug effects ; ENZYMES ; EVALUATION ; HIV Protease - chemistry ; HIV Protease - genetics ; HIV Protease - metabolism ; HIV Protease Inhibitors - chemical synthesis ; HIV Protease Inhibitors - chemistry ; HIV Protease Inhibitors - pharmacology ; HIV-1 - drug effects ; HIV-1 - enzymology ; HIV-1 - genetics ; Humans ; HYDROGEN ; Ligands ; Macrocyclic Compounds - chemical synthesis ; Macrocyclic Compounds - chemistry ; Macrocyclic Compounds - pharmacology ; Medical sciences ; Models, Molecular ; Molecular Conformation ; Mutation ; Pharmacology. Drug treatments ; PROTEINS ; SYNTHESIS</subject><ispartof>Journal of medicinal chemistry, 2009-12, Vol.52 (23), p.7689-7705</ispartof><rights>Copyright © 2009 American Chemical Society</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3</citedby><cites>FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22208050$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19746963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/1006098$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghosh, Arun K</creatorcontrib><creatorcontrib>Kulkarni, Sarang</creatorcontrib><creatorcontrib>Anderson, David D</creatorcontrib><creatorcontrib>Hong, Lin</creatorcontrib><creatorcontrib>Baldridge, Abigail</creatorcontrib><creatorcontrib>Wang, Yuan-Fang</creatorcontrib><creatorcontrib>Chumanevich, Alexander A</creatorcontrib><creatorcontrib>Kovalevsky, Andrey Y</creatorcontrib><creatorcontrib>Tojo, Yasushi</creatorcontrib><creatorcontrib>Amano, Masayuki</creatorcontrib><creatorcontrib>Koh, Yasuhiro</creatorcontrib><creatorcontrib>Tang, Jordan</creatorcontrib><creatorcontrib>Weber, Irene T</creatorcontrib><creatorcontrib>Mitsuya, Hiroaki</creatorcontrib><creatorcontrib>Argonne National Lab. (ANL), Argonne, IL (United States)</creatorcontrib><title>Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the protein backbone similar to darunavir (1) or inhibitor 2. The ring size, the effect of methyl substitution, and unsaturation within the macrocyclic ring structure were assessed. In general, cyclic inhibitors were significantly more potent than their acyclic homologues, saturated rings were less active than their unsaturated analogues and a preference for 10- and 13-membered macrocylic rings was revealed. The addition of methyl substituents resulted in a reduction of potency. Both inhibitors 14b and 14c exhibited marked enzyme inhibitory and antiviral activity, and they exerted potent activity against multidrug-resistant HIV-1 variants. Protein−ligand X-ray structures of inhibitors 2 and 14c provided critical molecular insights into the ligand-binding site interactions.</description><subject>08 HYDROGEN</subject><subject>AIDS VIRUS</subject><subject>Anti-HIV Agents - chemical synthesis</subject><subject>Anti-HIV Agents - chemistry</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>BONDING</subject><subject>Cell Line</subject><subject>Crystallography, X-Ray</subject><subject>DESIGN</subject><subject>Drug Design</subject><subject>Drug Resistance, Viral - drug effects</subject><subject>ENZYMES</subject><subject>EVALUATION</subject><subject>HIV Protease - chemistry</subject><subject>HIV Protease - genetics</subject><subject>HIV Protease - metabolism</subject><subject>HIV Protease Inhibitors - chemical synthesis</subject><subject>HIV Protease Inhibitors - chemistry</subject><subject>HIV Protease Inhibitors - pharmacology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - enzymology</subject><subject>HIV-1 - genetics</subject><subject>Humans</subject><subject>HYDROGEN</subject><subject>Ligands</subject><subject>Macrocyclic Compounds - chemical synthesis</subject><subject>Macrocyclic Compounds - chemistry</subject><subject>Macrocyclic Compounds - pharmacology</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Molecular Conformation</subject><subject>Mutation</subject><subject>Pharmacology. Drug treatments</subject><subject>PROTEINS</subject><subject>SYNTHESIS</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNptkUuOEzEQhi0EYsLAggsgC4kFUhr8Sj-WkBmYSOEhAohdq9pdnTjqtke2e1DfgDXn4TScBEeJZjasqlT6VFX__xPylLNXnAn-ej9UjOXV4uc9MuMLwTJVMnWfzBgTIhO5kGfkUQh7xpjkQj4kZ7wqVF7lckb-XGAwWzunm8nGXerDnH72LqKxf3_9Xpst2Jb-yDxMdBP9qOPocU4Pw7fG9W5rNPT08gb6EaJxlrqOAt2gNxgO_Ud3gz39ANo7PeneaHo1DmDpahhG61rsjDZo9US_Gz-GjB9vQ0C6sjvTmOh8oNHRpRsaiPTCj1v65fBlBKvxMXnQQR_wyamek2_vLr8ur7L1p_er5Zt1BqoQMVO6VFWHqXSiKDhbNEUjZaFEi7lqsBBlyQuJwLkssJHAm06xfCF0qxSHtpXn5PlxrwvR1EGbiHqnnbWoY82T9awqE_TyCCWtIXjs6mtvBvBTIupDTPVtTIl9dmSvx2bA9o485ZKAFycAQnK480muCbecEIKVbMHuONCh3rvR2-TDfw7-A1HcqYo</recordid><startdate>20091210</startdate><enddate>20091210</enddate><creator>Ghosh, Arun K</creator><creator>Kulkarni, Sarang</creator><creator>Anderson, David D</creator><creator>Hong, Lin</creator><creator>Baldridge, Abigail</creator><creator>Wang, Yuan-Fang</creator><creator>Chumanevich, Alexander A</creator><creator>Kovalevsky, Andrey Y</creator><creator>Tojo, Yasushi</creator><creator>Amano, Masayuki</creator><creator>Koh, Yasuhiro</creator><creator>Tang, Jordan</creator><creator>Weber, Irene T</creator><creator>Mitsuya, Hiroaki</creator><general>American Chemical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>OTOTI</scope></search><sort><creationdate>20091210</creationdate><title>Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance</title><author>Ghosh, Arun K ; Kulkarni, Sarang ; Anderson, David D ; Hong, Lin ; Baldridge, Abigail ; Wang, Yuan-Fang ; Chumanevich, Alexander A ; Kovalevsky, Andrey Y ; Tojo, Yasushi ; Amano, Masayuki ; Koh, Yasuhiro ; Tang, Jordan ; Weber, Irene T ; Mitsuya, Hiroaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>08 HYDROGEN</topic><topic>AIDS VIRUS</topic><topic>Anti-HIV Agents - chemical synthesis</topic><topic>Anti-HIV Agents - chemistry</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>BONDING</topic><topic>Cell Line</topic><topic>Crystallography, X-Ray</topic><topic>DESIGN</topic><topic>Drug Design</topic><topic>Drug Resistance, Viral - drug effects</topic><topic>ENZYMES</topic><topic>EVALUATION</topic><topic>HIV Protease - chemistry</topic><topic>HIV Protease - genetics</topic><topic>HIV Protease - metabolism</topic><topic>HIV Protease Inhibitors - chemical synthesis</topic><topic>HIV Protease Inhibitors - chemistry</topic><topic>HIV Protease Inhibitors - pharmacology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - enzymology</topic><topic>HIV-1 - genetics</topic><topic>Humans</topic><topic>HYDROGEN</topic><topic>Ligands</topic><topic>Macrocyclic Compounds - chemical synthesis</topic><topic>Macrocyclic Compounds - chemistry</topic><topic>Macrocyclic Compounds - pharmacology</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Molecular Conformation</topic><topic>Mutation</topic><topic>Pharmacology. Drug treatments</topic><topic>PROTEINS</topic><topic>SYNTHESIS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghosh, Arun K</creatorcontrib><creatorcontrib>Kulkarni, Sarang</creatorcontrib><creatorcontrib>Anderson, David D</creatorcontrib><creatorcontrib>Hong, Lin</creatorcontrib><creatorcontrib>Baldridge, Abigail</creatorcontrib><creatorcontrib>Wang, Yuan-Fang</creatorcontrib><creatorcontrib>Chumanevich, Alexander A</creatorcontrib><creatorcontrib>Kovalevsky, Andrey Y</creatorcontrib><creatorcontrib>Tojo, Yasushi</creatorcontrib><creatorcontrib>Amano, Masayuki</creatorcontrib><creatorcontrib>Koh, Yasuhiro</creatorcontrib><creatorcontrib>Tang, Jordan</creatorcontrib><creatorcontrib>Weber, Irene T</creatorcontrib><creatorcontrib>Mitsuya, Hiroaki</creatorcontrib><creatorcontrib>Argonne National Lab. (ANL), Argonne, IL (United States)</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>OSTI.GOV</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghosh, Arun K</au><au>Kulkarni, Sarang</au><au>Anderson, David D</au><au>Hong, Lin</au><au>Baldridge, Abigail</au><au>Wang, Yuan-Fang</au><au>Chumanevich, Alexander A</au><au>Kovalevsky, Andrey Y</au><au>Tojo, Yasushi</au><au>Amano, Masayuki</au><au>Koh, Yasuhiro</au><au>Tang, Jordan</au><au>Weber, Irene T</au><au>Mitsuya, Hiroaki</au><aucorp>Argonne National Lab. (ANL), Argonne, IL (United States)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2009-12-10</date><risdate>2009</risdate><volume>52</volume><issue>23</issue><spage>7689</spage><epage>7705</epage><pages>7689-7705</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>The structure-based design, synthesis, and biological evaluation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described. The inhibitors are designed to effectively fill in the hydrophobic pocket in the S1′−S2′ subsites and retain all major hydrogen bonding interactions with the protein backbone similar to darunavir (1) or inhibitor 2. The ring size, the effect of methyl substitution, and unsaturation within the macrocyclic ring structure were assessed. In general, cyclic inhibitors were significantly more potent than their acyclic homologues, saturated rings were less active than their unsaturated analogues and a preference for 10- and 13-membered macrocylic rings was revealed. The addition of methyl substituents resulted in a reduction of potency. Both inhibitors 14b and 14c exhibited marked enzyme inhibitory and antiviral activity, and they exerted potent activity against multidrug-resistant HIV-1 variants. Protein−ligand X-ray structures of inhibitors 2 and 14c provided critical molecular insights into the ligand-binding site interactions.</abstract><cop>Columbus, OH</cop><pub>American Chemical Society</pub><pmid>19746963</pmid><doi>10.1021/jm900695w</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2009-12, Vol.52 (23), p.7689-7705
issn 0022-2623
1520-4804
language eng
recordid cdi_osti_scitechconnect_1006098
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects 08 HYDROGEN
AIDS VIRUS
Anti-HIV Agents - chemical synthesis
Anti-HIV Agents - chemistry
Anti-HIV Agents - pharmacology
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
BONDING
Cell Line
Crystallography, X-Ray
DESIGN
Drug Design
Drug Resistance, Viral - drug effects
ENZYMES
EVALUATION
HIV Protease - chemistry
HIV Protease - genetics
HIV Protease - metabolism
HIV Protease Inhibitors - chemical synthesis
HIV Protease Inhibitors - chemistry
HIV Protease Inhibitors - pharmacology
HIV-1 - drug effects
HIV-1 - enzymology
HIV-1 - genetics
Humans
HYDROGEN
Ligands
Macrocyclic Compounds - chemical synthesis
Macrocyclic Compounds - chemistry
Macrocyclic Compounds - pharmacology
Medical sciences
Models, Molecular
Molecular Conformation
Mutation
Pharmacology. Drug treatments
PROTEINS
SYNTHESIS
title Design, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A41%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20Synthesis,%20Protein%E2%88%92Ligand%20X-ray%20Structure,%20and%20Biological%20Evaluation%20of%20a%20Series%20of%20Novel%20Macrocyclic%20Human%20Immunodeficiency%20Virus-1%20Protease%20Inhibitors%20to%20Combat%20Drug%20Resistance&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Ghosh,%20Arun%20K&rft.aucorp=Argonne%20National%20Lab.%20(ANL),%20Argonne,%20IL%20(United%20States)&rft.date=2009-12-10&rft.volume=52&rft.issue=23&rft.spage=7689&rft.epage=7705&rft.pages=7689-7705&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm900695w&rft_dat=%3Cacs_osti_%3Eb225873186%3C/acs_osti_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a472t-4c849fe4c8f277105b7b33742de64be7288173ea1137eb3a1bf40652cd441add3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19746963&rfr_iscdi=true